Immtech Announces Interim Analysis In Phase III African Sleeping Sickness Trial

Immtech Pharmaceuticals, Inc. (Amex: IMM) announced the completion of interim analysis of itsPhase III pivotal clinical trial of Immtech’s oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. [click link for full article]

More: continued here

Filed under: Clinical Trials on October 5th, 2007